THE EFFECT OF REPAGLINIDE AND METFORMIN ON EXTERNAL RESPIRATORY FUNCTION IN PATIENTS WITH DIABETES AND ISCHEMIC HEART DISEASE ASSOCIATED WITH OBESITY
Introduction: Over the past 20 years, numerous studies have examined the state of the bronchopulmonary system in type 2 diabetes mellitus (T2DM), but findings remain inconsistent. Some researchers report decreased external respiratory function (ERF) linked to metabolic shifts and disease complications, while others associate it with vascular pathology. There is also evidence of increased pulmonary ventilation in diabetes. The implementation of optimal glucose-lowering therapies to prevent complications, including pulmonary issues, remains a key concern in modern medicine.
The aim of the study is to evaluate the functional state of the external ventilation system in patients with type 2 diabetes mellitus in combination with coronary heart disease and obesity during treatment with repaglinide and metformin.
Materials and Methods: A 3–3.5-year observational study included 120 patients. The effect of repaglinide or metformin on patients with diabetes and concomitant diseases such as coronary heart disease and obesity has been studied. The data was analyzed using the following methods: computer spirometry and fiber-optic bronchoscopy.
Results: Patients with T2DM, especially those with IHD and obesity, showed both restrictive and obstructive pulmonary disorders, impaired gas exchange, and ventilation-perfusion mismatch. Repaglinide improved respiratory parameters, while metformin led to worsened spirometry indicators and increased bronchial resistance in most cases. Bronchoscopic findings confirmed nonspecific bronchial mucosal changes in 29.4% of patients.
Conclusion: Bronchopulmonary impairments in T2DM are primarily due to reduced ERF and increased bronchial resistance. Repaglinide appears more effective than metformin or gliclazide in improving respiratory function.
Urazalina Nailya - Candidate of Medical Sciences, Associate Professor of the Department of physiological disciplines named after honored scientist of the republic of Kazakhstan, professor T.A. Nazarova, NJSC "Semey Medical University", Semey, Kazakhstan; phone: 8 777 907 55 89, е-mail: hakim_15@mail.ru, https://orcid.org/0000-0003-0200-1763,
Tolubayeva Diana - Doctor PhD “Medical Center Hospital of the President affairs Administration of the Republic of Kazakhstan” Astana, https://orcid.org/0000-0003-3119-7814; е-mail: dianajianna@gmail.com; Cell phone +7 701 299 34 06.
*Corresponding author:
Zhautikova Saule - Professor of the Department of Physiology of NJSC «Karaganda Medical University», https://orcid.org/0009-0000-5712-7369; Karaganda, Kazakhstan.
Address: Gogol str. 40, Karaganda 100000, Kazakhstan.
е-mail: Zhautikova@qmu.kz;
Cell phone +7 701 299 34 07
1. Deng Y., et al. Effects of metformin on respiratory diseases: Current evidence and future perspectives. Frontiers in Pharmacology, 2022. 13, 856711. (DOI: 10.3389/fphar.2022.856711)
2. Kalra S., Gupta Y., Kumar A. Repaglinide: An Overview. Journal of the Association of Physicians of India, 2015. 63(4), 60–63.
3. Kim H.L., et al. Impact of obesity and metabolic syndrome on respiratory function: A narrative review. Journal of Obesity & Metabolic Syndrome, 2021. 30(2), 101–110. DOI: 10.7570/joms.2021.30.2.101
4. Kostovski M., Simeonovski V., Mironska K., Tasic V., Gucev Z. Metabolic Profiles in Obese Children and Adolescents with Insulin Resistanceю. Open Access Maced J Med Sci. 2018. 15. 6(3):511-518 https://oamjms.eu/index.php/mjms/article/view/oamjms.
5. Król E., Rutkowski B. Influence of Metformin on Pulmonary Function in Diabetic Patients. Polish Archives of Internal Medicine, 2015. 125(3), 182–189.
6. Kolahian S., Leiss V., Nürnberg B. Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord. 2019 Sep. 20(3):303-319. doi: 10.1007/s11154-019-09516-w. PMID: 31637580; PMCID: PMC7102037.
7. Lee J.S., et al. The pleiotropic effects of meglitinides in cardiovascular and renal protection. International Journal of Molecular Sciences, 2020. 21(11), 3845. (DOI: 10.3390/ijms21113845)
8. Long C., Fan W., Liu Y., Hong K. Stress hyperglycemia is associated with poor outcome in critically ill patients with pulmonary hypertension. Front Endocrinol (Lausanne). 2024 Feb 23;15:1302537. doi: 10.3389/fendo.2024.1302537. PMID: 38464971; PMCID: PMC10924302.
9. Li M., Chi X., Wang Y. et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Sig Transduct Target Ther. 2022. 7, 216. https://doi.org/10.1038/s41392-022-01073-0
10. Li W., Ning Y., Ma Y. et al. Association of lung function and blood glucose level: a 10-year study in China. BMC Pulm Med. 2022. 22, 444 https://doi.org/10.1186/s12890-022-022
11. Suleman S., Madsen A.L., Ängquist L.H., Schubert M., Linneberg A., Loos R.J.F., Hansen T., Grarup N. Genetic Underpinnings of Fasting and Oral Glucose-stimulated Based Insulin Sensitivity Indices. J Clin Endocrinol Metab. 2024 Oct 15;109(11):2754-2763. doi: 10.1210/clinem/dgae275. PMID: 38635292; PMCID: PMC11479690.
12. Sharma A., Müller K., Zhang Y., Ivanov D. A comprehensive review on diabetic cardiomyopathy: Pathophysiology, imaging assessment and potential metabolic-targeted strategies. European Journal of Endocrinology, 2025. 192(6), R127–R150. https://doi.org/10.1530/EJE-25-0147
13. Peng Y., Zhong GC., Wang, L. et al. Chronic obstructive pulmonary disease, lung function and risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies. BMC Pulm Med. 2020. 20, 137. https://doi.org/10.1186/s12890-020-1178-y
14. Zhao Y., et al. Mechanisms of impaired lung function in diabetes mellitus: An updated review. Frontiers in Physiology, 2022. 13, 856711. (DOI: 10.3389/fphys.2022.856711)
Количество просмотров: 34
Категория статей:
Оригинальное исследование
Библиографическая ссылка
Zhautikova S.B., Urazalina N.M., Tolubayeva D.B. The effect of repaglinide and metformin on external respiratory function in patients with diabetes and ischemic heart disease associated with obesity // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (3), pp. 36-41. doi 10.34689/SH.2025.27.3.004Похожие публикации:
EPIDEMIOLOGY, RESOURCE DISTRIBUTION, AND MANAGEMENT CHALLENGES OF CHRONIC HEART FAILURE IN KAZAKHSTAN: A NATIONAL RETROSPECTIVE ANALYSIS
PREVALENCE OF POLYMORPHISMS IN WARFARIN METABOLISM-RELATED GENES AMONG THE KAZAKH POPULATION
NEUROLOGICAL COMPLICATIONS IN EXTRACORPOREAL MEMBRANE OXYGENATION: RISK FACTORS FOR THE DEVELOPMENT OF ACUTE CEREBROVASCULAR EVENTS
THE EFFECT OF REPAGLINIDE AND METFORMIN ON EXTERNAL RESPIRATORY FUNCTION IN PATIENTS WITH DIABETES AND ISCHEMIC HEART DISEASE ASSOCIATED WITH OBESITY
RETROSPECTIVE ANALYSIS OF PATIENTS WITH OBLITERATING ATHEROSCLEROSIS OF THE LOWER EXTREMITY ARTERIES IN THE ABAI REGION OF THE REPUBLIC OF KAZAKHSTAN